By proceeding, you agree to our Terms of Use and Privacy Policy.
Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization.
29-30 March 2022
Dedicated to exploring microbiome research and strategies for commercialisation and product development, we bring together KOLs to present a series of R&D case studies. Topics covered include gut health and disease, advances beyond the gut including
Event Ended
USA
Paid
San Diego
24-25 May 2022
10thMicrobiome R&D and Business Collaboration Forum: Europe Dedicated to exploring microbiome research and strategies for commercialisation and product development
Netherlands
The Hague
21-23 June 2022
The 7th Microbiome Movement - Drug Development Summit?returns to Boston at a pivotal time. As the microbiome therapeutic space matures, with more indications being pursued and more companies conducting trials, the focus of this event - now in its 7th
Boston
16-17 November 2022
The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis.
Phage therapies have shown promise in compassionate use, but limited success of double blind randomised controlled trials has slowed progression through the clinic.
31-02 February 2023
From hypothetical to reality, the first ever approval of a microbiome-based therapy is here and is set to propel the industry forward, expanding across a wide range of diseases.
UK
London
28-30 June 2023
Join the 8th Microbiome Movement Drug Development Summit, an event that brings together top drug developers and technology enablers to advance the field of microbiome drug development. With a focus on cutting-edge science, preclinical and clinical tr
19-20 October 2023
The 2023 Microbiome & Probiotics R&D and Business Collaboration Forum comes at an exciting time for the microbiome industry. The recent FDA approvals for Seres Therapeutics and MaaT Pharma (Phase III Clinical Trial), along with Vedanta Biosciences’ s
It is an exciting time for the microbiome industry and recent FDA approvals and successful fundraising point towards the industry’s potential for therapeutic applications. Developments in the Skin space such as partnerships, collaboration, and licens
14-16 November 2023
Join a like-minded community of 300 scientists and entrepreneurs as passionate about the microbiome as you are. Microbiome Connect was born with the simple mission to bring innovative products to patients, and we bring together experts approaching th